HC Wainwright Cuts REGENXBIO (NASDAQ:RGNX) Price Target to $34.00

REGENXBIO (NASDAQ:RGNX) had its price objective cut by HC Wainwright from $36.00 to $34.00 in a research note published on Monday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for REGENXBIO’s Q1 2025 earnings at ($1.21) EPS, Q2 2025 earnings at ($1.20) EPS, Q3 2025 earnings at ($1.20) EPS, Q4 2025 earnings at ($1.19) EPS and FY2025 earnings at ($4.80) EPS.

Several other analysts have also recently commented on the company. Chardan Capital reiterated a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a research report on Friday, March 14th. Raymond James started coverage on REGENXBIO in a research report on Friday, February 7th. They set an “outperform” rating and a $27.00 price target for the company. The Goldman Sachs Group cut REGENXBIO from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $38.00 to $14.00 in a research report on Tuesday, February 11th. Royal Bank of Canada reissued an “outperform” rating and set a $30.00 price objective on shares of REGENXBIO in a research note on Tuesday, January 21st. Finally, StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, March 7th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $33.88.

REGENXBIO Price Performance

REGENXBIO stock opened at $8.50 on Monday. REGENXBIO has a 12 month low of $5.62 and a 12 month high of $23.14. The stock has a market capitalization of $421.13 million, a PE ratio of -1.69 and a beta of 1.35. The business has a 50 day simple moving average of $7.28 and a 200-day simple moving average of $8.93.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. The firm had revenue of $21.21 million during the quarter, compared to analysts’ expectations of $23.70 million. On average, equities research analysts anticipate that REGENXBIO will post -4.84 EPS for the current fiscal year.

Hedge Funds Weigh In On REGENXBIO

Several large investors have recently modified their holdings of the business. Redmile Group LLC lifted its stake in shares of REGENXBIO by 7.1% in the 3rd quarter. Redmile Group LLC now owns 4,892,902 shares of the biotechnology company’s stock valued at $51,327,000 after purchasing an additional 323,100 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of REGENXBIO by 67.0% in the 4th quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company’s stock valued at $31,975,000 after buying an additional 1,659,206 shares during the period. Millennium Management LLC raised its holdings in shares of REGENXBIO by 406.3% in the 4th quarter. Millennium Management LLC now owns 1,322,344 shares of the biotechnology company’s stock valued at $10,222,000 after buying an additional 1,061,187 shares during the period. Balyasny Asset Management L.P. raised its holdings in shares of REGENXBIO by 6.0% in the 4th quarter. Balyasny Asset Management L.P. now owns 1,187,102 shares of the biotechnology company’s stock valued at $9,176,000 after buying an additional 66,993 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in shares of REGENXBIO by 1.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,171,422 shares of the biotechnology company’s stock valued at $9,054,000 after buying an additional 21,234 shares during the period. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.